Jim Cramer can’t help but wonder if this old dog of a stock has learned new tricks.» Read More
Looking for earnings clues and names to bet on, with CNBC's Melissa Lee and the Options Action traders.
These 10 stocks had been out of favor. But now, they're kind of ‘in crowd.’
I think the short-term pullback in the stock market is over, says Ron Insana. Here's why.
JMP Securities' Alex Gauna has a counter-intuitive idea on how to play Apple when its upcoming stock split makes shares much, much cheaper.
Some of the names on the move ahead of the open.
The "Fast Money" traders share their final trades of the day.
It's never too soon to start planning ahead if you hope to buy your first home within the next year.
Apple becomes the fourth member of the S&P 500 to announce a split in 2014.
Some analysts say the market may be quietly sniffing out a higher rate of inflation.
Jim Cramer looks at many metrics as he decides where to put money. He’s just spotted something very bullish.
Right now cloud stocks are out of favor. But they won’t always be that way.
You'd think we'd get a pretty good lift from Apple and Facebook earnings as well as talk of more M&A activity, but it all faded.
Microsoft investors may be bullish about CEO Satya Nadella, but he will have to really start proving himself in the next quarter.
Veteran trader Art Cashin breaks down the market conditions that could panic "baby bears" and send stocks to new record highs.
A new survey shows that many on Wall Street agree with Michael Lewis that U.S. equity markets aren't fair.
Apple's growth overseas and surprising 7-for-1 stock split was a "victory for all the Apple shareholders," CNBC's Jim Cramer said Thursday.
Ian Harnett, a European analyst at Absolute Strategy Research, believes stocks will rally another 20 percent in 2014.
Here's how the wealthiest people may manage their fortunes in 25 years.
Investors liked what they saw in Facebook and Apple, but Wall Street fell after a slew of earnings and data couldn't sustain the bounce.
U.S. drugmaker Eli Lilly reported lower-than-expected quarterly revenue as it was hurt by disappointing sales of its cancer and diabetes drugs.
Get the best of CNBC in your inbox